Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01378091 · ClinicalTrials.gov registry record · Phase 1
Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer
A Phase 1 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT01378091 is a Phase 1 study that has completed, run by Columbia University. The registered enrollment target is 64 participants.
The verdict
NCT01378091, a Phase 1 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
Primary objectives: To determine the maximum tolerated doses (MTDs) of daily lenalidomide and docetaxel given every three weeks and prednisone, as combination therapy to subjects with androgen independent prostate cancer To evaluate the safety profile of the combination of daily lenalidomide and every three week docetaxel and prednisone when given to subjects with androgen independent prostate cancer Secondary objective: To explore the anti-tumor activity of the combination of daily lenalidomide and every 3 week docetaxel and prednisone when given to subjects with androgen independent prostate cancer.
Interventions
- DRUG Docetaxel
- DRUG Lenalidomide
- DRUG Prednisone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2005-08 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01378091
The ClinicalTrials.gov registry entry for NCT01378091 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT01378091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01378091 about?
NCT01378091 is a clinical study titled "Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer". Primary objectives: To determine the maximum tolerated doses (MTDs) of daily lenalidomide and docetaxel given every three weeks and prednisone, as combination therapy to subjects with androgen independent prostate cancer To evaluate the safety profile of the combination of daily lenalidomide and e...
What is the current status of trial NCT01378091?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2005-08. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01378091?
The interventions under investigation include: Docetaxel (DRUG), Lenalidomide (DRUG), Prednisone (DRUG).
Who is sponsoring clinical trial NCT01378091?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.